Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

This study has been completed.

First Received: September 13, 2005 Last Updated: September 25, 2006 History of Changes

Sponsored by:	Sanwa Kagaku Kenkyusho Co., Ltd.
Information provided by:	Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:	NCT00213122

Purpose

In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.

Condition	Intervention	Phase
Type 2 Diabetes Mellitus	Drug: miglitol	Phase III

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin Miglitol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Single Blind, Placebo Control, Crossover Assignment, Efficacy Study

Eligibility

Ages Eligible for Study:	20 Years to 74 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

type2 diabetes
postprandial plasma glucose levels ≧180mg/dl

Exclusion Criteria:

type1 diabetes
AST(GOT) or ALT(GPT) ≧100IU/l
creatinine ≧2.0mg/dl

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213122

Locations

Japan

Ibaraki, Japan

Sponsors and Collaborators

Sanwa Kagaku Kenkyusho Co., Ltd.

Investigators

Study Director:

Clinical Promotiom Group

Sanwa Kagaku Kenkyusho Co., Ltd.

More Information

No publications provided

Study ID Numbers:	MG1007
Study First Received:	September 13, 2005
Last Updated:	September 25, 2006
ClinicalTrials.gov Identifier:	NCT00213122 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

alpha-glucosidase inhibitor,Insulin

Study placed in the following topic categories:

Miglitol
Hypoglycemic Agents
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus

Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder
Insulin

Additional relevant MeSH terms:

Miglitol
Hypoglycemic Agents
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Diabetes Mellitus, Type 2

Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009